Biomerica, Inc. (BMRA)
BMRA Stock Price Chart
Explore Biomerica, Inc. interactive price chart. Choose custom timeframes to analyze BMRA price movements and trends.
BMRA Company Profile
Discover essential business fundamentals and corporate details for Biomerica, Inc. (BMRA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
7 Sept 1984
Employees
64.00
Website
https://www.biomerica.comCEO
Zackary S. Irani
Description
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.
BMRA Financial Timeline
Browse a chronological timeline of Biomerica, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 27 Aug 2026
EPS estimate is -$1.20, while revenue estimate is $3.63m.
Earnings released on 13 Apr 2026
EPS came in at -$0.44 surpassing the estimated -$1.20 by +63.33%, while revenue for the quarter reached $1.12m , missing expectations by -69.17%.
Earnings released on 9 Apr 2026
Earnings released on 14 Jan 2026
EPS came in at -$0.45 , while revenue for the quarter reached $1.21m .
Earnings released on 14 Oct 2025
EPS came in at $0.00 , while revenue for the quarter reached $1.38m .
Stock split effective on 21 Apr 2025
Shares were split 1 : 8 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Apr 2025
EPS came in at -$0.48 , while revenue for the quarter reached $1.12m .
Earnings released on 14 Jan 2025
EPS came in at -$0.06 , while revenue for the quarter reached $1.64m .
Earnings released on 15 Oct 2024
EPS came in at -$0.08 , while revenue for the quarter reached $1.81m .
Earnings released on 12 Apr 2024
EPS came in at -$0.11 , while revenue for the quarter reached $1.02m .
Earnings released on 16 Jan 2024
EPS came in at -$0.09 , while revenue for the quarter reached $1.57m .
Earnings released on 12 Oct 2023
EPS came in at -$0.07 , while revenue for the quarter reached $1.71m , missing expectations by -93.56%.
Earnings released on 25 Aug 2023
EPS came in at -$0.10 falling short of the estimated $0.04 by -350.00%, while revenue for the quarter reached $1.11m , missing expectations by -85.61%.
Earnings released on 14 Apr 2023
EPS came in at -$0.12 falling short of the estimated $0.02 by -700.00%, while revenue for the quarter reached $1.11m , missing expectations by -85.57%.
Earnings released on 13 Jan 2023
EPS came in at -$0.12 , while revenue for the quarter reached $1.48m , missing expectations by -47.07%.
Earnings released on 13 Oct 2022
EPS came in at -$0.16 falling short of the estimated -$0.02 by -700.00%, while revenue for the quarter reached $1.64m , missing expectations by -39.35%.
Earnings released on 29 Aug 2022
EPS came in at -$0.14 falling short of the estimated -$0.12 by -16.67%, while revenue for the quarter reached $5.30m , beating expectations by +146.96%.
Earnings released on 14 Apr 2022
EPS came in at -$0.01 surpassing the estimated -$0.10 by +90.00%, while revenue for the quarter reached $7.66m , beating expectations by +164.43%.
Earnings released on 12 Jan 2022
EPS came in at -$0.09 falling short of the estimated -$0.08 by -12.50%, while revenue for the quarter reached $4.65m , beating expectations by +60.24%.
Earnings released on 14 Oct 2021
EPS came in at -$0.12 matching the estimated -$0.12, while revenue for the quarter reached $1.26m , missing expectations by -29.90%.
Earnings released on 27 Aug 2021
EPS came in at -$0.12 falling short of the estimated -$0.10 by -20.00%, while revenue for the quarter reached $1.05m .
BMRA Stock Performance
Access detailed BMRA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
